Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 141

Results For "24"

2051 News Found

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies
Clinical Trials | February 28, 2024

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies

The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies


Concord Biotech receives GMP certificate from Kenya regulator
Drug Approval | February 26, 2024

Concord Biotech receives GMP certificate from Kenya regulator

The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series


Max Healthcare to acquire land parcel in Lucknow for new hospital
News | February 26, 2024

Max Healthcare to acquire land parcel in Lucknow for new hospital

The board gave in-principle approval for expansion of company's footprint in Lucknow


Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility
Drug Approval | February 26, 2024

Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility

The observations do not pose any risk to site's compliance standards or its business continuity


India implementing largest digital programme for TB surveillance
News | February 24, 2024

India implementing largest digital programme for TB surveillance

Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi


Briefs: Suven Pharmaceuticals, Remedium Lifecare and Kilitch Drugs India
News | February 24, 2024

Briefs: Suven Pharmaceuticals, Remedium Lifecare and Kilitch Drugs India

Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully


Moderna posts Q4 2023 revenue at US$ 2.8 billion
News | February 23, 2024

Moderna posts Q4 2023 revenue at US$ 2.8 billion

Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance


Pfizer and AIF’s Project Parivartan demonstrates progress in addressing antimicrobial resistance
News | February 22, 2024

Pfizer and AIF’s Project Parivartan demonstrates progress in addressing antimicrobial resistance

Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms


Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
News | February 20, 2024

Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides

IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China


Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery
News | February 18, 2024

Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery

Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery